Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...

Are These 5 Undervalued Stocks Ready to Break Out? Executives at a healthcare investor event outlined commercial launch plans ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Alnylam (ALNY), and BioMarin Pharmaceutical (BMRN) were among the gainers on Tuesday after Citi launched the SMid Cap Biotech group with a bullish view, citing compelling growth and catalyst outlook.

An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their ...

How Ionis Pharmaceuticals Stock Has Been Trading Ionis Pharmaceuticals (IONS) has drawn investor attention recently as the stock moved 2.3% in the latest session, with shorter term returns differing ...

The updated fair value estimate for Ionis Pharmaceuticals has shifted from US$93.90 to US$96.73 per share, a modest move that still matters if you are tracking valuation closely. This change comes as ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on ...